insights_auto
Outlook: 89.5% bullish·0.0% bearish
Go to analysischevron_right
DHER34:BVMF
Danaher Corporation Bdr
R$41.10
0.00%
(0.00) 1D
Oct 22, 5:06:00 PM GMT-3 · BRL
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DHER34...
Mkt. cap
162.16B
Avg. vol.
1.89K
Volume
0.00
52-wk high
R$45.87
52-wk low
R$27.94
Shares outstanding
703.53M
No. of employees
59K
Mkt. cap
162.16B
Avg. vol.
1.89K
Volume
0.00
52-wk high
R$45.87
52-wk low
R$27.94
Shares outstanding
703.53M
No. of employees
59K
News stories
From web sources and news partners
Investing.com
·
1 day ago
Stifel raises Danaher stock price target to $260 on growth outlook
The Globe and Mail
·
2 days ago
Why Danaher Stock Bounced Higher Today
Seeking Alpha
·
2 days ago
Danaher Corporation 2026 Q3 - Results - Earnings Call Presentation (NYSE:DHR) 2026-10-21
Profile
Danaher Corporation is an American healthcare company headquartered in Washington, D.C.. It develops products used for advances in biotechnology, life sciences, and diagnostics. The company operates three divisions: biotechnology, which develops products for the development of therapeutics; life sciences, which develops products to identify causes of disease, new therapies, and to test and manufacture new drugs, vaccines and gene editing technologies; and diagnostics, which develops instruments, consumables, and software and services to diagnose diseases. Danaher was founded in 1984 by brothers Steven Rales and Mitchell Rales; it was named after Danaher Creek in Western Montana, where the brothers came up with the idea for the company while fishing.
The company is ranked 180th on the Fortune 500 and 241st on the Forbes Global 2000. Wikipedia
About Danaher Corporation Bdr
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 6.05B | 6.84B | 5.95B | 6.26B |
Cost of goods sold | 2.53B | 2.86B | 2.36B | 2.61B |
Cost of revenue | 2.53B | 2.86B | 2.36B | 2.61B |
Research and development expenses | 378.00M | 438.00M | 387.00M | 412.00M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 1.89B | 2.03B | 1.84B | 2.01B |
Operating expense | 2.27B | 2.46B | 2.23B | 2.42B |
Total operating expenses | 4.80B | 5.32B | 4.59B | 5.03B |
Operating income | 1.26B | 1.52B | 1.36B | 1.24B |
Other non operating income | - | -87.00M | - | - |
EBT including unusual items | 1.08B | 1.37B | 1.24B | 1.08B |
EBT excluding unusual items | 1.19B | 1.39B | 1.33B | 1.19B |
Income tax expense | 168.00M | 190.00M | 206.00M | 208.00M |
Effective tax rate | 15.61% | 13.84% | 16.68% | 19.29% |
Other operating expenses | - | - | - | - |
Net income | 908.00M | 1.20B | 1.03B | 870.00M |
Net profit margin | 15.00% | 17.51% | 17.29% | 13.89% |
Earnings per share | 1.89 | 2.23 | 2.06 | 1.94 |
Interest and investment income | 3.00M | 13.00M | 27.00M | 61.00M |
Interest expense | -67.00M | -55.00M | -63.00M | -107.00M |
Net interest expenses | -64.00M | -42.00M | -36.00M | -46.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 1.88B | 2.14B | 1.99B | 1.90B |
Gain or loss from assets sale | -9.00M | 9.00M | - | - |